Paclitaxel loaded poly(L-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill

Biomaterials

Volumn 21, Issue 19, 2000, Pages 1959-1969

  Liggins, R T ^a   D'Amours, S ^b   Demetrick, J S ^c   MacHan, L S ^d   Burt, H M ^e  

^a Angiotech Pharmaceuticals Inc   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c V2G 2G8 ^*  (Canada)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Carcinomatosis; Intraperitoneal Administration; Microspheres; Paclitaxel; Poly(L lactic acid)

Indexed keywords

CELLS; CONTROLLED DRUG DELIVERY; ONCOLOGY; POLYESTERS; SURGERY;

CARCINOMATOSIS; PACLITAXEL; POLYLACTIC ACID;

BIOMATERIALS;

MICROSPHERE; PACLITAXEL; POLYLACTIC ACID; POLYVINYL ALCOHOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMATOUS PERITONITIS; CECUM; CLEARANCE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; HISTOLOGY; INTESTINE RESECTION; LYMPHATIC SYSTEM; MALE; NONHUMAN; PARTICLE SIZE; PERITONEAL CAVITY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SURGICAL WOUND; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CARBON DIOXIDE; CECUM; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; INSUFFLATION; INTRAOPERATIVE COMPLICATIONS; LACTIC ACID; MALE; MICROSPHERES; PACLITAXEL; PERITONEAL CAVITY; POLYMERS; RATS; RATS, WISTAR;

EID: 0034308354     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(00)00080-6     Document Type: Article

References (51)

1. Rowinsky E.K. Update on the antitumor activity of paclitaxel. Ann Pharmacother. 28:1994;S18-22.
2. Cascinu S., Graziano F., Cardarelli N.et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 9:1998;307-310.
3. 1 mice. Cancer Chemother Pharmacol. 34:1994;465-471.
4. Alberts D.S., Liu P.Y., Hannigan E.V.et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med. 335:1996;1950-1955.
5. Monsarrat B., Mariel E., Crois S.et al. Taxol metabolism. Isolation and identification of three major metabolites in rat bile. Drug Metab Dispos. 18:1990;895-901.
6. Rowinsky E.K., Donehower R.C., Jones R.J., Tucker R.W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res. 48:1988;4093-4100.
7. Markman M., Rowinsky E., Hakes T.et al. Phase I trial of intraperitoneal Taxol. a gynecologic oncology group study J Clin Oncol. 10:1992;1485-1491.
8. ®). Semin Oncol. 20:1993;31-39.
9. Allen L. The peritoneal stomata. Anat Rec. 67:1936;89-102.
10. Flessner MF, Parker RJ, Sieber SM. Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rat. Am J Physiol 1983;244:H89-96.
11. Abernethy N.J., Chiun W., Hay J.B., Rodela H., Oreopoulos D., Johnston M.G. Lymphatic drainage of the peritoneal cavity in sheep. Am J Physiol. 260:1991;353-358.
12. Abu-Hijleh M.F., Scothorne R.J. Regional lymph drainage routes from the diaphragm in the rat. Clin Anat. 7:1994;181-188.
13. Ludwig J. Trapping of calibrated microspheres in rat lymph nodes. Lymphology. 1:1971;18-24.
14. Edman P., Sjöholm I. Acrylic microspheres in vivo. II. The effect in rat of L-asparaginase given in microparticles of poly-acrylamide. J Pharmacol Exp Ther. 211:1979;663-667.
15. Allen L., Weatherford T. Role of fenestrated basement membrane in lymphatic absorpeiton from peritoneal cavity. Am J Physiol. 197:1959;551-554.
16. Abu-Hijleh M.F., Habbal O.A., Moqattash S.T. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat. 186:1995;453-467.
17. Jacquet P., Averbach A.M., Stephen A.D., Sugarbaker P.H. Cancer recurrence following laparoscopic colectomy. Dis Col Rectum. 38:1995;1110-1114.
18. Hughes E.S., McDermot F.T., Polglase A.L., Johnson W.R. Tumour recurrence in the abdominal wall scar tissue after large-bowel cancer surgery. Dis Col Rectum. 26:1983;571-572.
19. Ramos J.M., Gupta S., Anthone G.J., Ortega A.E., Simons A.J., Beart R.W. Laparoscopy and colon cancer. is the port site at risk? A preliminary report Arch Surg. 129:1994;897-900.
20. Demetrick J.S., Liggins R.T., Machan L., Davis N.L., Burt H.M., Hunter W.L. The development of a novel intraperitoneal tumor-seeding prophylactic. Am J Surg. 173:1997;403-406.
21. Kulkarni R.K., Moore E.G., Hegyeli A.F.et al. Biodegradble poly(lactic acid) polymers. J Biomed Mater Res. 5:1971;169-181.
22. Holland S.J., Tighe B.J., Gould P.L. Polymers for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems. J Control Rel. 4:1986;155-180.
23. Kishida A., Dressman J.B., Yoshioka S., Aso Y., Takeda Y. Some determinants of morphology and release rates from poly(L)lactic acid microspheres. J Control Rel. 13:1990;83-89.
24. Jalil R., Nixon J.R. Microencapsulation using poly(L-lactic acid) I. microcapsule properties affected by the preparative technique J Microencap. 6:1989;473-484.
25. Burt H.M., Jackson J.K., Bains S.K.et al. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly(D,L-lactic acid). Cancer Lett. 88:1995;73-79.
26. Lin SY, Ho LT, Chiou HL. Microencapsulation and controlled release of insulin from polylactic acid microcapsules. Biomater Med Dev Art Org 1985-6;13:187-201.
27. Mumper R.J., Jay M. Poly(L-lactic acid) microspheres containing neutron-activatable holium-165: a study of the physical characteristics of microspheres before and after irradiation in a nuclear reactor. Pharm Res. 9:1992;149-154.
28. Wang Y.M., Sato H., Horikoshi I. In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J Control Rel. 49:1997;157-166.
29. Kwong A.K., Chou S., Sun A.M., Sefton M.V., Goosen M.F.A. In vitro and in vivo release of insulin from poly(lactic acid) microbeads and pellets. J Control Rel. 4:1986;47-62.
30. Dordunoo S.K., Jackson J.K., Arsenault L.A., Oktaba A.M.C., Hunter W.L., Burt H.M. Taxol encapsulation in poly(ε-caprolactone) microspheres. Cancer Chemother Pharmacol. 36:1995;279-282.
31. Wang Y.M., Sato H., Adachi I., Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, Taxol. Chem Pharm Bull. 44:1996;1935-1940.
32. Baker R. Controlled release of biologically active agents. 1987;Academic Press, New York.
33. Makino K., Arakawa M., Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull. 33:1985;1195-1201.
34. Lam K.H., Niewenhuis P., Molenaar I., Esslebrugge H., Feijen J., Dijkstra P.J., Schakenraad J.M. Biodegradation of porous versus non-porous poly(L-lactic acid) films. J Mater Sci: Mater Med. 5:1994;181-189.
35. Çiftçi K., Hincal A.A., Kas H.S., Ercan M.T., Ruacan S. Microspheres of 5-fluorouracil using poly(DL-lactic acid): in vitro release properties and distribution in mice after i.v. administration. Eur J Pharm Sci. 1:1994;249-258.
36. Langer R. Controlled drug delivery systems. Chem Eng Commun. 6:1980;1-48.
37. Johnstone P.A.S., Rhode D.C., Swartz S.E., Fetter J.E., Wexner S.D. Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. J Clin Oncol. 14:1996;1950-1956.
38. Clair D.G., Lautz D.B., Brooks D.C. Rapid development of umbilical metastases after laparoscopic cholecystectomy for unsuspended gallbladder carcinoma. Surgery. 113:1993;355-358.
39. Thomas W.M., Eaton M.C., Hewett P.J. A proposed model for the movement of cells within the abdominal cavity during carbon dioxide insufflation and laparoscopy. Austral NZ J Surg. 66:1996;105-106.
40. Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, Trochanowski B, Lin S, Toomasi F, Brennan M. Phase II trial of postoperative adjuvant interperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993;11:425-33.
41. Cahan M.A., Walter K.A., Calvin A.M.et al. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol. 33:1994;441-444.
42. Skipper D., Jeffrey M.J., Cooper A.J., Alexander P., Taylor I. Enhanced growth of tumour cells in healing colonic anastomoses and laparotomy wounds. Int J Colorectal Dis. 4:1989;172-177.
43. Murthy S.M., Goldschmidt R.A., Roa L.N., Ammirati M., Buchmann T., Scanlon E.F. The influence of surgical trauma on experimental metastases. Cancer. 64:1989;2035-2044.
44. Jacquet P, Averbach AM, Stephen AD, Sugarbaker PH. Cancer recurrence following laparoscopic colectomy. Dis Colon Rectum 1995;38:l110-4.
45. Jacquet P., Sugarbaker P.H. Influence of wound healing in gastrointestinal cancer recurrence. Wounds. 7:1995;40-47.
46. Itoi K., Tabata C.Y., Ike O.et al. In vivo suppressive effects of copoly(glycolic/L-lactic acid) microspheres containing CDDP on murine tumor cells. J Control Rel. 42:1996;175-184.
47. Leenslag J.W., Pennings A.J., Bos R.R.M., Rozema F.R., Boering G. Resorbable materials of poly(L-lactide). VII. In vivo and in vitro degradation. Biomaterials. 8:1987;311-314.
48. Pistner H., Bendix D.R., Mühling, Reuther J.F. Poly(L-lactide): a long-term degradation study in vivo. Biomaterials. 14:1993;291-298.
49. Vert M., Li S.M., Spenlehauer G., Guerin P. Bioresorbability and biocompatibility of aliphatic polyesters. J Mater Sci: Mater Med. 3:1992;432-446.
50. Markman M. Intraperitoneal chemotherapy in the treatment of ovarian cancer. Ann Med. 28:1996;293-296.
51. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl J Med. 13:1995;1004-1014.